Acuta Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Acuta Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-74,500	Closed	-$1.51M	–	40
2023 Q4	$1.51M	Buy	+74,500	New	+$980K	0.85%	29
2023 Q2	–	Sell	-104,753	Closed	-$1.8M	–	36
2023 Q1	$1.8M	Buy	+104,753	New	+$2.04M	1.33%	20
2021 Q2	–	Sell	-20,000	Closed	-$868K	–	43
2021 Q1	$868K	Hold	20,000	–	–	0.31%	42
2020 Q4	$829K	Buy	+20,000	New	+$826K	0.23%	46

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's FDMT Position: Q1 2024 in Review

Acuta Capital Partners sold out of 4D Molecular Therapeutics (FDMT) in Q1 2024, closing a stake of 74,500 shares — an estimated $1.51M sold.

Acuta Capital Partners first reported a position in FDMT in Q4 2020 and held it in 4 quarters. The position peaked at $1.8M in Q1 2023. 147 funds tracked by Wall St. Rank hold FDMT as of Q1 2024.

Acuta Capital Partners reported no remaining 4D Molecular Therapeutics position as of Q1 2024 after selling out during the quarter.
Acuta Capital Partners sold 74,500 4D Molecular Therapeutics shares in Q1 2024, an estimated $1.51M.
Acuta Capital Partners first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 4 quarters.
Acuta Capital Partners's 4D Molecular Therapeutics position peaked at $1.8M in Q1 2023.
147 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.